MohamedLSorrorMD

Oncology • Seattle, WA

Hematologic Oncology

Assistant Professor, Medicine, University of Washington School of Medicine

Join to view full profile

Dr. Sorror is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sorror's full profile

Already have an account?

Office
825 Eastlake Ave E
Seattle, WA 98109
Phone+1 206-288-1000

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2008 - 2010
University of Assiut Faculty of MedicineClass of 1993

Certifications & Licensure

MT State Medical License 2022 - 2026
WA State Medical License 2005 - 2026

Clinical Trials

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2004 Dec 01
Completed
Phase 2
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Start of enrollment: 2010 Mar 18
Completed
Phase 2
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant Start of enrollment: 2012 May 01
Terminated
Phase 2
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
Completed
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant Start of enrollment: 2016 Mar 01
Withdrawn
Phase 2
Comparing Different Methods for Collection of Comorbidity Data Per the HCT-CI Start of enrollment: 2013 Mar 22
Completed
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases Start of enrollment: 2019 Aug 15
Recruiting
Phase 2, Phase 3
Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704) Start of enrollment: 2019 Jul 19
Completed
Join now to see all

Publications & Presentations

PubMed

6 citations
Cardio-Oncology and the Intersection of Cancer and Cardiotoxicity: The Role of Palliative Care.
Richard Cheng, James N. Kirkpatrick, Mohamed L. Sorror, Ana Barac
JACC. Cardiooncology. 2019-12-01
198 citations
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Lori Muffly, Marcelo C. Pasquini, Michael Martens, Ruta Brazauskas, Xiaochun Zhu
Blood. 2017-08-31
2205 citations
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
Mohamed L. Sorror, Michael B. Maris, Rainer Storb, Frédéric Baron, Brenda M. Sandmaier
Blood. 2005-10-15

Journal Articles

Pre-Transplant Expressions of microRNAs, Comorbidities, and Post-Transplant Mortality
Mohamed L Sorror, Muneesh Tewari, Nature

Abstracts/Posters

Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Mohamed L. Sorror, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Fred Hutch at ASH: Press Briefing on CAR T-cell Therapy, CRISPR for Blood Disorders, MoreNovember 26th, 2018
Age No Longer a Barrier to Stem Cell Transplantation for Older PatientsNovember 2nd, 2011
Use of Low-Toxicity Conditioning Regimen Prior to Cell Transplantation Appears Promising for Older Adults with Blood, Bone Marrow CancersNovember 1st, 2011

Grant Support

Impact Of Comorbidities On Outcomes Of Allogeneic TransplantationNational Heart, Lung, And Blood Institute2011–2012
Impact Of Comorbidities On Outcomes Of Allogeneic TransplantationNational Heart, Lung, And Blood Institute2007–2008